Learn how to stay healthy during COVID-19 with our free guide —
Coronavirus: A guide to staying healthy (and sane) while stuck indoors
| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 75 |
| Sex | Both Genders |
| Age Range | 30-44, 45-64 |
| Body Types | Obese, Overweight |
In adult outpatients with atypical depression given 600mcg chromium (as picolinate) daily over the course of eight weeks, supplementation failed to outperform placebo in the primary intention to treat (overall depressive symptoms as assessed by HAM-D) but when assessing the parameters associated with food intake and carbohydrate cravings chromium appeared to outperform placebo by reducing cravings and food consumption.
In persons with high baseline carbohydrate cravings, there was also an improvement in genital symptoms (ie. libido) relative to placebo.
